Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Cidara Therapeutics (NASDAQ: CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its participation in two upcoming investor conferences. The company will present at the RBC Global Healthcare Conference on May 21, 2025, at 10:00 AM ET, and the Jefferies Global Healthcare Conference on June 4, 2025, at 11:40 AM ET.
Both presentations will be available via live webcast through Cidara's investor relations website, with replays accessible for at least 30 days. The company will also engage in one-on-one meetings with investors during these events.
Cidara Therapeutics (NASDAQ: CDTX), un'azienda biotecnologica specializzata in terapie coniugate farmaco-Fc tramite la sua piattaforma Cloudbreak®, ha annunciato la sua partecipazione a due prossimi convegni per investitori. La società presenterà al RBC Global Healthcare Conference il 21 maggio 2025 alle 10:00 ET e al Jefferies Global Healthcare Conference il 4 giugno 2025 alle 11:40 ET.
Entrambe le presentazioni saranno disponibili in diretta streaming sul sito web delle relazioni con gli investitori di Cidara, con le registrazioni accessibili per almeno 30 giorni. La società parteciperà inoltre a incontri individuali con gli investitori durante questi eventi.
Cidara Therapeutics (NASDAQ: CDTX), una empresa biotecnológica especializada en terapias conjugadas fármaco-Fc a través de su plataforma Cloudbreak®, ha anunciado su participación en dos próximas conferencias para inversores. La compañía presentará en la RBC Global Healthcare Conference el 21 de mayo de 2025 a las 10:00 AM ET y en la Jefferies Global Healthcare Conference el 4 de junio de 2025 a las 11:40 AM ET.
Ambas presentaciones estarán disponibles vía webcast en vivo a través del sitio web de relaciones con inversores de Cidara, con repeticiones accesibles durante al menos 30 días. La compañía también mantendrá reuniones individuales con inversores durante estos eventos.
Cidara Therapeutics (NASDAQ: CDTX)는 Cloudbreak® 플랫폼을 통해 약물-Fc 접합 치료제를 전문으로 하는 생명공학 회사로, 다가오는 두 개의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사는 2025년 5월 21일 오전 10시(동부시간)에 RBC 글로벌 헬스케어 컨퍼런스에서, 2025년 6월 4일 오전 11시 40분(동부시간)에 Jefferies 글로벌 헬스케어 컨퍼런스에서 발표할 예정입니다.
두 발표 모두 Cidara 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 제공되며, 최소 30일간 다시보기 서비스를 이용할 수 있습니다. 또한 회사는 이 행사 기간 동안 투자자들과 일대일 미팅도 진행할 예정입니다.
Cidara Therapeutics (NASDAQ : CDTX), une société biotechnologique spécialisée dans les thérapeutiques conjuguées médicament-Fc via sa plateforme Cloudbreak®, a annoncé sa participation à deux prochaines conférences pour investisseurs. La société présentera lors de la RBC Global Healthcare Conference le 21 mai 2025 à 10h00 ET, et lors de la Jefferies Global Healthcare Conference le 4 juin 2025 à 11h40 ET.
Les deux présentations seront disponibles en webcast en direct via le site des relations investisseurs de Cidara, avec des rediffusions accessibles pendant au moins 30 jours. La société tiendra également des réunions individuelles avec les investisseurs lors de ces événements.
Cidara Therapeutics (NASDAQ: CDTX), ein Biotechnologieunternehmen, das sich auf Wirkstoff-Fc-Konjugat-Therapeutika über seine Cloudbreak®-Plattform spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird auf der RBC Global Healthcare Conference am 21. Mai 2025 um 10:00 Uhr ET und auf der Jefferies Global Healthcare Conference am 4. Juni 2025 um 11:40 Uhr ET präsentieren.
Beide Präsentationen werden live per Webcast über die Investor-Relations-Website von Cidara verfügbar sein, mit Wiederholungen, die mindestens 30 Tage lang zugänglich sind. Das Unternehmen wird während dieser Veranstaltungen auch Einzelgespräche mit Investoren führen.
- None.
- None.
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences.
Event: RBC Global Healthcare Conference
Date: Wednesday, May 21, 2025
Time: 10:00 AM ET
Event: Jefferies Global Healthcare Conference
Date: Wednesday, June 4, 2025
Time: 11:40 AM ET
The live webcast for the presentations can be accessed in the Investors section on the Company’s website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days.
Cidara will also participate in one-on-one investor meetings during these events.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When will Cidara Therapeutics (CDTX) present at the RBC Global Healthcare Conference in 2025?
What is Cidara Therapeutics' (CDTX) main technology platform?
When is Cidara's (CDTX) presentation at the Jefferies Global Healthcare Conference?
How long will the replays of Cidara's (CDTX) conference presentations be available?
